← Back to Search

Cancer Vaccine

Survivin Vaccine for Multiple Myeloma

Phase < 1
Waitlist Available
Led By Frederick Locke, M.D.
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months post treatment
Awards & highlights

Study Summary

This trial will test the safety and effectiveness of a new cancer vaccine, given before and after an autologous hematopoietic cell transplant (HCT).

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months post treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Therapeutic procedure
Rate of Complete Response (CR)
Secondary outcome measures
Number of Participants With Improved Immunologic Response

Trial Design

1Treatment groups
Experimental Treatment
Group I: Survivin Vaccine and Autologous HCTExperimental Treatment4 Interventions
Dendritic Cell Survivin Vaccine (DC:AdmS) and Autologous Hematopoietic Cell Transplantation (HCT). Participants will receive 1 pre-transplant survivin vaccine, 7-30 days prior to stem cell apheresis collection. After the first survivin vaccination, participants will be mobilized with Granulocyte-colony Stimulating Factor (G-CSF). A second survivin vaccine will be administered on day +21 (between day+20 and +34) after HCT. All participants will be co-immunized with Prevnar 13 at each time they receive the survivin vaccine.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Survivin Vaccine
2016
Completed Early Phase 1
~20
Autologous Hematopoietic Cell Transplantation
2016
Completed Early Phase 1
~20
Prevnar 13
2012
Completed Phase 4
~13260
Granulocyte-colony Stimulating Factor
2016
Completed Early Phase 1
~20

Find a Location

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
542 Previous Clinical Trials
135,478 Total Patients Enrolled
29 Trials studying Multiple Myeloma
2,099 Patients Enrolled for Multiple Myeloma
Frederick Locke, M.D.Principal InvestigatorH. Lee Moffitt Cancer Center and Research Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)
2016. "Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02851056.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top